Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp Alfa Combination Therapy in Multiple Myeloma
2022-001418-20Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2022
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of modakafusp alfa in multiple myeloma (MM) (3 arms), sponsored by Takeda. Primary endpoint: Primary safety and tolerability. Started Oct 2022; status: completed.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-001418-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001418-20.